Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gatekeeping procedures with clinical trial applications.

Alex Dmitrienko1, Ajit C Tamhane

  • 1Eli Lilly and Company, Indianapolis, IN 46285, USA. dmitrienko_alex@lilly.com

Pharmaceutical Statistics
|June 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testing One Primary and Two Secondary Endpoints in a Two-Stage Group Sequential Trial With Extensions.

Statistics in medicine·2025
Same author

Modern approaches for evaluating treatment effect heterogeneity from clinical trials and observational data.

Statistics in medicine·2024
Same author

Multiplicity adjustments for the Dunnett procedure under heterokcedasticity.

Biometrical journal. Biometrische Zeitschrift·2023
Same author

Overview of modern approaches for identifying and evaluating heterogeneous treatment effects from clinical data.

Clinical trials (London, England)·2023
Same author

Quantitative MRI Biomarkers as Potential Inclusion Body Myositis Clinical Trial Endpoints.

Neurology·2022
Same author

A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.

Pharmaceutical statistics·2022
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

This paper reviews gatekeeping procedures for analyzing hierarchically ordered multiple objectives, focusing on their use in clinical trials. These methods help manage complex testing strategies for multiple endpoints.

Area of Science:

  • Statistics
  • Biostatistics
  • Clinical Trial Methodology

Background:

  • Multiplicity is a common issue in clinical trials with multiple objectives.
  • Gatekeeping procedures offer a structured approach to control Type I error rates when testing multiple endpoints.
  • Hierarchically ordered objectives require specialized statistical methods.

Purpose of the Study:

  • To provide an overview of gatekeeping procedures for hierarchically ordered multiple objectives.
  • To review main classes of gatekeeping procedures, including serial, parallel, and tree-based methods.
  • To illustrate the application and properties of these procedures using clinical trial examples.

Main Methods:

  • Focus on gatekeeping procedures based on marginal p-values.

Related Experiment Videos

  • Discussion of extensions utilizing the joint distribution of p-values.
  • Review of serial, parallel, and tree gatekeeping procedures accounting for logical restrictions.

    • Main Results:

    • Gatekeeping procedures provide a framework for testing multiple hypotheses in a controlled manner.
    • Different gatekeeping procedures (serial, parallel, tree) offer flexibility based on objective hierarchy and logical constraints.
    • Procedures based on marginal p-values are highlighted, with extensions to joint distributions noted.

    Conclusions:

    • Gatekeeping procedures are essential for robust multiplicity control in clinical trials.
    • The reviewed methods, particularly those based on marginal p-values, offer practical solutions for complex trial designs.
    • Understanding these procedures is crucial for designing and interpreting clinical trials with multiple objectives.